Beta Bionics, Inc.
NASDAQ:BBNXMedical - Equipment & Services
+$0.42 today
- Market cap
- $644.70M
- Beta
- 3.39
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.50
Volume 1.38M
Average 0.99M
BBNX Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Beta Bionics, Inc.NASDAQ: BBNX
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables growth accelerates
Q1 FY2026 accounts payables of $3.33M (cash outflow) rose 3336.1% year over year, ahead of the -212.9% change in trailing-twelve-month accounts payables.
Context
- Accounts payables amounted to 2.1% of revenue in FY2025, down 0.2 pp from a year earlier.
- Accounts payables increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +3336.1% holds above the trailing-twelve-month pace of -212.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 2.1M USD
- Year-over-year change
- +38.5%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.1M | +38.5% |
| FY2024 | 2024-12-31 | 1.52M | +111.6% |
| FY2023 | 2023-12-31 | 716K | +1029.9% |
| FY2022 | 2022-12-31 | (77K) | — |
Accounts Payables vs competitors
How BBNX compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -212.9% is the lowest of 6, against a peer median of -10.3%.
- Accounts payables amounts to 1.0% of revenue for BBNX, versus a peer median of 1.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $245.6M USD | -36.9% | +5.5% | 4.9% | |
MMEDMiniMed Group, Inc. Common Stock | LTM Jul 2026 | $237M USD | — | +43.1% | 7.4% |
| LTM Jun 2026 | $16.5M USD | -10.3% | — | 0.5% | |
| LTM Mar 2026 | $10.24M USD | +155.8% | -55.0% | 1.0% | |
| LTM Mar 2026 | $7.85M USD | +272.4% | — | 2.2% | |
| LTM Mar 2026 | $1.44M USD | -64.1% | — | — | |
| LTM Mar 2026 | $1.14M USD | -212.9% | — | 1.0% | |
| LTM Jun 2026 | DKK 0 DKK | — | — | 0.0% | |
| Peer median (excluding BBNX) | — | -10.3% | +5.5% | 1.6% | |
Competitors are the stored peer set for BBNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (64.75M) | (44.1M) | (54.76M) | (73.2M) |
| Depreciation & Amortization | 2.09M | 2.09M | 2.28M | 2.88M |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.1M | 5.66M | 6.38M | 16.38M |
| Change in Working Capital | (2.79M) | (6.36M) | (12.15M) | (8.99M) |
| Accounts Receivables | 0 | (4.49M) | (7.62M) | (5.16M) |
| Inventory | 0 | (1.19M) | (11.44M) | (9.88M) |
| Accounts Payables | (77K) | 716K | 1.52M | 2.1M |
| Other Working Capital | (2.71M) | (682K) | 5.39M | 3.95M |
| Other Non-Cash Items | (854K) | 10.27M | 9.96M | 12.01M |
| Operating Cash Flow | (60.21M) | (32.45M) | (48.27M) | (50.93M) |
| Capital Expenditures | (772K) | (402K) | (3.4M) | (5.3M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (69.3M) | (72.13M) | (327.51M) |
| Sales of Investments | 0 | 0 | 72M | 170M |
| Other Investing Activities | 3K | (69.29M) | 50K | 0 |
| Investing Cash Flow | (769K) | (69.69M) | (3.48M) | (162.81M) |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Common Stock Issued | 389K | 29K | 55.62M | 214.87M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 389K | 101.03M | 0 | 0 |
| Financing Cash Flow | 56.78M | 101.03M | 55.62M | 214.87M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | (4.2M) | (1.11M) | 3.87M | 1.14M |
| Free Cash Flow | (60.98M) | (32.85M) | (51.67M) | (56.22M) |
Beta Bionics, Inc.
NASDAQ:BBNX
Intrinsic Alpha fair value
Locked
Current Price
$14.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.